SBTX Profile
Silverback Therapeutics Inc (SBTX) is a clinical-stage biopharmaceutical company focused on developing immune-modulating therapies to treat patients with various types of cancer, chronic viral infections, and autoimmune diseases. The company's lead product candidate, SBT6050, is a first-in-class, systemically administered, anti-ILT7 antibody that is currently in Phase 1 clinical development for the treatment of advanced solid tumors.
SBTX's approach involves targeting specific immune pathways in order to activate or inhibit immune cells, thereby modulating the body's immune response. The company's proprietary ImmunoTAC platform is designed to enable the targeted delivery of potent immune modulators to specific cells or tissues within the body, with the goal of increasing the efficacy of these drugs while minimizing their toxicity.
In addition to SBT6050, SBTX has a pipeline of preclinical and discovery-stage product candidates targeting a range of immune pathways and mechanisms. The company has partnerships with several other biopharmaceutical companies, including Bristol Myers Squibb, Genentech, and BeiGene, focused on developing and commercializing its proprietary platform and product candidates. SBTX is headquartered in Seattle, Washington, and was founded in 2016.
|
